STUDY OF ORAL LOBUCAVIR IN PATIENTS WITH RECURRENT GENITAL HERPES

复发性生殖器疱疹患者口服洛布卡韦的研究

• 批准号: 6566712
• 负责人: STEPHEN K TYRING
• 金额: $ 27.93万
• 依托单位: UNIVERSITY OF TEXAS MED BR GALVESTON
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-12-01 至 2002-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6566712
• 关键词: antiviral agents; clinical research; clinical trial phase I; dosage; drug screening /evaluation; genital herpes; human subject; human therapy evaluation; microorganism disease chemotherapy; oral administration; placebos; relapse /recurrence; volunteer

We will test the efficacy and safety of a new antiviral drug, lobucavir, from Bristol Myers Squibb, in immunocompetent subjects with recurrent genital herpes infections. Volunteers in this randomized, double-blind, placebo-controlled study will receive one of three doses of lobucavir or placebo twice daily for five days. Follow-up visits to the clinic will continue until the genital herpes lesions are completely healed. Lobucavir has proven a potent antiviral in tissue culture and animal model studies. Therefore, the findings from these studies may help in developing a genital herpes treatment that will hasten healing of lesions and reduce the severity or duration of the pain and discomfort associated with the infection.

我们将在患有复发性生殖器疱疹感染的免疫功能正常受试者中测试百时美施贵宝的新型抗病毒药物洛布卡韦的有效性和安全性。 在这项随机、双盲、安慰剂对照研究中，志愿者将接受三剂洛布卡韦中的一剂或安慰剂，每天两次，持续五天。 门诊随访将持续进行，直至生殖器疱疹皮损完全愈合。 在组织培养和动物模型研究中，洛布卡韦已被证明是一种有效的抗病毒药物。因此，这些研究的结果可能有助于开发生殖器疱疹治疗方法，加速病变愈合并减少与感染相关的疼痛和不适的严重程度或持续时间。